Declining rates of oropharyngeal candidiasis and carriage of Candida albicans associated with trends toward reduced rates of carriage of fluconazole-resistant C. albicans in human immunodeficiency virus-infected patients

Clinical Infectious Diseases

Volumn 27, Issue 5, 1998, Pages 1291-1294

  Martins, Marcelo D ^a,b   Lozano Chiu, Mario ^a   Rex, John H ^a,b  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE;

ANTIBIOTIC RESISTANCE; ARTICLE; CANDIDA ALBICANS; CANDIDIASIS; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MAJOR CLINICAL STUDY; OROPHARYNX; PREVALENCE; PRIORITY JOURNAL;

EID: 0032457450     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/515006     Document Type: Article

References (24)

1. Bartlett JG. Protease inhibitors for HIV infection [editorial]. Ann Intern Med 1996; 124:1086-8.
2. Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. JAMA 1997; 277:1962-9.
3. Hammer SM, Katzenstein DA, Hughes MD, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med 1996; 335:1081-90.
4. Delta Coordinating Committee. Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 1996; 348:283-91.
5. Deeks SG, Smith M, Holodniy M, Kahn JO. HIV-1 protease inhibitors: a review for clinicians. JAMA 1997; 277:145-53.
6. Katlama C, Ingrand D, Loveday C, et al. Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients: a randomized controlled comparison with zidovudine monotherapy. JAMA 1996; 276:118-25.
7. Graham NM, Hoover DR, Park LP, et al. Survival in HIV-infected patients who have received zidovudine: comparison of combination therapy with sequential monotherapy and continued zidovudine monotherapy. Ann Intern Med 1996; 124:1031-8.
8. Gazzard B. What we know so far. AIDS 1996; 10(suppl 1):S3-7.
9. Hicks CB, Myers SA, Giner J. Resolution of intractable molluscum contagiosum in a human immunodeficiency virus - infected patient after institution of antiretroviral therapy with ritonavir. Clin Infect Dis 1997; 24: 1023-5.
10. Carr A, Cooper DA. Restoration of immunity to chronic hepatitis B infection in HIV-infected patient on protease inhibitor [letter]. Lancet 1997; 349:995-6.
11. Elliot B, Aromin I, Gold R, Flanigan T, Mileno M. 2.5-Year remission of AIDS-associated progressive multifocal leukoencephalopathy with combined antiretroviral therapy [letter]. Lancet 1997; 349:850.
12. Power C, Nath A, Aoki FY, Bigio MD. Remission of progressive multifocal leukoencephalopathy following splenectomy and antiretroviral therapy in a patient with HIV infection [letter]. N Engl J Med 1997; 336: 661-2.
13. Martins MD, Lozano-Chiu M, Rex JH. Point prevalence of carriage of fluconazole-resistant Candida in the oropharynx of HIV-infected patients. Clin Infect Dis 1997; 25:843-6.
14. Greenspan D, Greenspan JS, Schiodt M, Pindborg JJ. AIDS and the mouth: diagnosis and management of oral lesions. Copenhagen: Munksgaard, 1991.
15. Sullivan DJ, Westerneng TJ, Haynes KA, Bennett DE, Coleman DC. Candida dubliniensis sp. nov.: phenotypic and molecular characterization of a novel species associated with oral candidosis in HIV-infected individuals. Microbiology 1995; 141:1507-21.
16. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard. NCCLS document M27-A. Wayne, Pennsylvania: National Committee for Clinical Laboratory Standards, 1997.
17. Sangeorzan JA, Bradley SF, He X, et al. Epidemiology of oral candidiasis in HIV-infected patients: colonization, infection, treatment, and emergence of fluconazole resistance. Am J Med 1994; 97:339-46.
18. Maenza JR, Merz WG, Romagnoli MJ, Keruly JC, Moore RD, Gallant JE. Infection due to fluconazole-resistant Candida in patients with AIDS: prevalence and microbiology. Clin Infect Dis 1997; 24:28-34.
19. Millon L, Manteaux A, Reboux G, et al. Fluconazole-resistant recurrent oral candidiasis in human immunodeficiency virus-positive patients: persistence of Candida albicans strains with the same genotype. J Clin Microbiol 1994; 32:1115-8.
20. Calvet HM, Yeaman MR, Filler SG. Reversible fluconazole resistance in Candida albicans: a potential in vitro model. Antimicrob Agents Chemother 1997; 41:535-9.
21. Coleman DC, Sullivan DJ, Bennett DE, Moran GP, Barry HJ, Shanley DB. Candidiasis: the emergence of a novel species, Candida dubliniensis. AIDS 1997; 11:557-67.
22. Sullivan D, Haynes K, Bille J, et al. Widespread geographic distribution of oral Candida dubliniensis strains in human immunodeficiency virus-infected individuals. J Clin Microbiol 1997; 35:960-4.
23. Rex JH, Rinaldi MG, Pfaller MA. Resistance of Candida species to fluconazole. Antimicrob Agents Chemother 1995; 39:1-8.
24. Denning DW. Can we prevent azole resistance in fungi? Lancet 1995; 346:454-5.